Second Dicerna Hepatic Disease Target Option Exercise

Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target  From Research Collaboration with Dicerna Collaboration seeks to develop novel treatments for chronic liver diseases,  including nonalcoholic steatohepatitis (NASH) 
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news